Development of novel pain relief agents acting through the selective activation of the delta-opioid receptor
by
Dondio G SmithKline Beecham S.p.A.,
Department of Medicinal Chemistry,
Milan, Italy.
massimo_dondio@sbpharm.com
Farmaco 2000 Mar; 55(3):178-80

ABSTRACT

A continuing effort in the development of non-peptide delta-opioid agonists as possible safe and effective pain relief agents has been seen in the last years. Novel potent and selective delta-opioid agonists based on the pirrolomorphinan framework have been designed, synthesised and biologically characterised in our laboratories. In particular, compound 7 (SB 235863) proved the concept that a selective delta-opioid agonist may be a valuable pain relief agent free of the unwanted side-effects usually associated with narcotic analgesics such as morphine.

Mu
CREB
Feeding
Delta agonists
Fentanyl and ketamine
Dynorphin and dopamine
Kappa upregulation and addiction
Opioids, brain stimulation and reward
Cholecystokinin and delta opioid receptors

Refs
HOME
HedWeb
BLTC Research
Designer Drugs
Paradise-Engineering
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?